News Sentiment

CGTX sentiment intelligence

Cognition Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.09 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.8% over one week, -9.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.8% Price reacting lower
Trend fit Trend inactive -9.9% over four weeks
Fair value -11.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 8
GlobeNewswire 6
Investing.com 3
simplywall.st 3
Moomoo 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 14
Analyst action 4
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
GlobeNewswire Direct company coverage

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will participate in a fireside chat at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. She will discuss the ongoing START study and the planned Phase 3 trial for zervimesine (CT1812) in

Tone
Positive 70/100
Event
Market update
Published
14 Jul 2026 02:50
Source
GlobeNewswire
TradingView Direct company coverage

Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX

This article displays financial data for Cognition Therapeutics, Inc. (NASDAQ:CGTX), specifically its enterprise value to EBIT forward. It indicates various data sources and copyright information related to the financial figures presented. The page also includes navigation elemen

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 16:43
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX

The article prominently displays the financial metric "Enterprise value to revenue forward" for Cognition Therapeutics, Inc. (NASDAQ: CGTX). It provides a brief financial overview of the company on the Nasdaq Stock Market. The content primarily focuses on the stock's financial da

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 18:40
Source
TradingView
TradingView Direct company coverage

Number of shareholders of Cognition Therapeutics, Inc. – NASDAQ:CGTX

This article section is about the number of shareholders for Cognition Therapeutics, Inc. (NASDAQ: CGTX). It provides details related to the data for the number of shareholders, indicating the period, value, change, and percentage change. The content also notes that the data is m

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 13:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX

The article focuses on the "Price to sales forward" metric for Cognition Therapeutics, Inc. (NASDAQ:CGTX). It provides market data and financial information for the company, accessible through TradingView.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 09:39
Source
TradingView
TradingView Direct company coverage

Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Cognition Therapeutics, Inc.'s SEC filings and other important company documents, including earnings reports, conference transcripts, and corporate presentations. These documents outline the company's financial performance, operationa

Tone
Positive 74/100
Event
Earnings
Published
02 Jul 2026 06:10
Source
TradingView
Investing.com South Africa Direct company coverage

H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment

H.C. Wainwright maintained a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ:CGTX) after the company announced positive FDA feedback regarding its drug development program for psychosis associated with dementia with Lewy bodies. The FDA agreed that psychosis c

Tone
Positive 75/100
Event
Analyst action
Published
01 Jul 2026 13:54
Source
Investing.com South Africa
Moomoo Direct company coverage

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

The article discusses Cognition Therapeutics' (NASDAQ:CGTX) cash burn rate, highlighting its significant spending on operating expenses and research and development relative to its cash reserves. It notes the company's strong cash position but emphasizes the need for efficient ca

Tone
Negative 39/100
Event
Balance sheet
Published
30 Jun 2026 09:39
Source
Moomoo
www.marketscreener.com Direct company coverage

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index

Cognition Therapeutics, Inc. (NasdaqCM: CGTX) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina,

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 06:10
Source
www.marketscreener.com
TradingView Direct company coverage

Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX)

This article provides an overview of Cognition Therapeutics, Inc. (NASDAQ: CGTX), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key financial metrics, upcoming earnings reports, and answers frequently asked questio

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:10
Source
TradingView
Market source Direct company coverage

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Cognition Therapeutics has received positive feedback from the FDA regarding key aspects of a pivotal study for zervimesine (CT1812) in treating psychosis associated with dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis could be an approvable outcome, and the co

Tone
Positive 75/100
Event
Market update
Published
25 Jun 2026 10:09
Source
Market source
Stock Titan Direct company coverage

FDA says DLB psychosis could be approvable in Cognition trial plan

Cognition Therapeutics (NASDAQ: CGTX) announced that the FDA has agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome, aligning on key aspects of a pivotal Phase 3 trial for zervimesine (CT1812). The registrational program is expect

Tone
Negative 39/100
Event
Market update
Published
24 Jun 2026 18:22
Source
Stock Titan
Stocktwits Direct company coverage

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

Cognition Therapeutics received positive feedback from the FDA regarding its planned Phase 3 study for Zervimesine in DLB psychosis, with the trial expected to begin in mid-2027. Despite this, the company's shares dropped over 33% due to investor concerns about the lengthy timeli

Tone
Negative 14/100
Event
Market update
Published
24 Jun 2026 11:47
Source
Stocktwits
Seeking Alpha Direct company coverage

Cognition, FDA agree on late-stage trial for dementia therapy

Cognition Therapeutics (CGTX) saw a premarket increase of ~5% after announcing alignment with the FDA on key aspects of a late-stage trial. The trial will test its lead asset, zervimesine, for a specific form of dementia. This agreement marks a significant step forward for the co

Tone
Positive 81/100
Event
Market update
Published
24 Jun 2026 11:41
Source
Seeking Alpha
Stock Titan Direct company coverage

Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine

Cognition Therapeutics announced FDA alignment on key aspects of a pivotal Phase 3 trial for zervimesine (CT1812) to treat psychosis in dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis is an approvable outcome, paving the way for a New Drug Application. The stud

Tone
Positive 74/100
Event
Market update
Published
24 Jun 2026 11:41
Source
Stock Titan
Quiver Quantitative Direct company coverage

Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis

Cognition Therapeutics announced that the FDA has agreed on the pivotal trial design for its candidate treatment, zervimesine, for psychosis associated with dementia with Lewy bodies (DLB). This alignment marks a significant step towards regulatory approval, addressing an urgent

Tone
Positive 81/100
Event
Regulatory and legal
Published
24 Jun 2026 11:40
Source
Quiver Quantitative
Investing.com Nigeria Direct company coverage

Form DEF 14A Cognition Therapeutics Inc For: 23 June By Investing.com

This article from Investing.com announces the filing of Form DEF 14A by Cognition Therapeutics Inc. for June 23. It provides no further details about the filing but includes various market data and other news headlines.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 02:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs

Cognition Therapeutics director Jack A. Khattar was granted 25,000 restricted stock units (RSUs) as an equity award. These RSUs, valued at $0.00 each for the grant, will vest in full on the earlier of June 17, 2027, or the company's next annual stockholders' meeting, provided he

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

RSU grant lifts Cognition Therapeutics (CGTX) director Peggy Wallace’s holdings

Cognition Therapeutics director Peggy Wallace received a grant of 25,000 Restricted Stock Units (RSUs) as compensation for her board service. These RSUs, which are a contingent right to receive common stock, will vest in full by June 17, 2027, or the company's next annual meeting

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Cognition Therapeutics (CGTX) granted 25,000 RSUs

Cognition Therapeutics director Ellen B. Richstone was granted 25,000 restricted stock units (RSUs) as compensation, not through an open-market trade. These RSUs, which vest on June 17, 2027, or the company's next annual stockholder meeting contingent on her continued board servi

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity

This article reports on insider trading activity at COGNITION THERAPEUTICS INC (CGTX) based on a Form 4 filing. Director Aaron G.L. Fletcher was granted 25,000 Restricted Stock Units (RSUs) which vest on the earlier of June 17, 2027, or the company's next annual stockholder meeti

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:10
Source
Stock Titan
Investing.com Direct company coverage

H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news

H.C. Wainwright maintained a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ:CGTX) after the company secured a Notice of Allowance for a patent covering a polymorphic crystalline form of its lead drug candidate, zervimesine. This patent provides protection thr

Tone
Positive 71/100
Event
Analyst action
Published
22 Jun 2026 12:09
Source
Investing.com